At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 178 enrolled
Drug / intervention
CSF-1 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Double-Masked, Vehicle-Controlled, Evaluation of the Safety of CSF-1 in Presbyopic Subjects
In Brief
A Phase 3 clinical trial evaluating CSF-1 and Vehicle for Presbyopia. Completed, enrolled 178 participants across 12 sites.
Detailed Summary
This is a multi-center, double-masked, vehicle-controlled study. The purpose of the study is to evaluate the safety of CSF-1 compared with vehicle in presbyopic subjects. Subjects will be treated for at least 6 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPresbyopia
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
Enrollment StartApr 2022
First PostedMay 2022
Primary CompletionDec 2022
TodayJul 2026
First PostedMay 26, 2022
Enrollment StartApr 22, 2022
Primary CompletionDec 1, 2022
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 4.1 years ago
Interventions
CSF-1drug
One drop bilaterally twice daily for at least 6 weeks
Vehicledrug
One drop bilaterally twice daily for at least 6 weeks